Welcome to our dedicated page for Kenvue news (Ticker: KVUE), a resource for investors and traders seeking the latest updates and insights on Kenvue stock.
Kenvue Inc. (NYSE: KVUE) is described as the world’s largest pure-play consumer health company by revenue, with a portfolio of science-backed brands such as Aveeno®, BAND-AID® Brand, Johnson’s®, Listerine®, Neutrogena®, Tylenol® and Zyrtec®. This news page aggregates company announcements, press releases and market-moving updates related to KVUE stock and Kenvue’s global consumer health operations.
Readers can find earnings news, including quarterly results where Kenvue reports net sales trends, organic sales performance, gross profit and operating income margins, and diluted and adjusted earnings per share. These releases often include management commentary on operating priorities, productivity initiatives, supply chain optimization efforts and updated outlooks for the fiscal year, along with explanations of non-GAAP measures such as Adjusted gross profit margin, Adjusted operating income margin, Adjusted net income, Adjusted EBITDA margin, Adjusted effective tax rate, Free cash flow and Organic sales.
The feed also covers strategic and corporate developments. In 2025, Kenvue announced a comprehensive review of strategic alternatives, leadership changes including a CEO transition, and a definitive agreement under which Kimberly-Clark Corporation will acquire all outstanding shares of Kenvue common stock in a cash and stock transaction, as detailed in joint press releases and a Form 8-K. Updates on this planned acquisition, board decisions and related shareholder communications are key topics for investors following KVUE news.
Additional items include dividend declarations by Kenvue’s Board of Directors, highlighting the company’s approach to returning capital to shareholders, and partnership and innovation news, such as the collaboration with Albert Invent to apply AI to Kenvue’s research and development processes. Together, these categories give investors, analysts and consumers a consolidated view of how Kenvue manages its brand portfolio, financial performance and strategic direction. Bookmark this page to quickly access the latest official Kenvue updates relevant to KVUE stock.
Kenvue (NYSE: KVUE), the world's largest pure-play consumer health company, has announced a dividend increase. The company's Board of Directors declared a quarterly dividend of $0.2075 per share on its common stock, representing a 1.2% increase from the previous quarter.
The dividend will be payable on August 27, 2025, to shareholders of record as of August 13, 2025. Kenvue's portfolio includes well-known brands such as Aveeno, BAND-AID, Johnson's, Listerine, Neutrogena, and Tylenol.
Kenvue (NYSE: KVUE), the world's largest pure-play consumer health company, will release its Q2 2025 financial results before market open on August 7, 2025. The company will host a conference call and webcast at 8:30 a.m. ET to discuss the results.
Investors can access the conference call by dialing 877-407-8835 (U.S.) or +1 201-689-8779 (international). A live webcast will be available at investors.kenvue.com, with a replay accessible after the event.
Kenvue (NYSE:KVUE), the world's largest pure-play consumer health company, announced significant leadership changes and strategic initiatives. The company has appointed Kirk Perry as Interim CEO, replacing Thibaut Mongon, effective immediately. Perry brings over 30 years of consumer products and technology experience.
The Board has initiated a comprehensive strategic review to unlock shareholder value, considering portfolio optimization and operational improvements. Additionally, Kenvue released preliminary Q2 2025 results showing a 4.0% decline in net sales and organic sales decrease of 4.2%, with adjusted diluted EPS expected between $0.28 and $0.29.
The company will provide updated full-year 2025 guidance during its complete Q2 earnings release on August 7, 2025.Kenvue Inc. (NYSE: KVUE), known for brands like Neutrogena®, Listerine®, Aveeno®, and Tylenol®, has announced its participation in the Deutsche Bank's dbAccess Global Consumer Conference in Paris, France. The company's leadership team, including CEO Thibaut Mongon, CFO Amit Banati, and Group President Carlton Lawson, will engage in a fireside chat on June 3, 2025, at 6:00 a.m. ET / 12:00 p.m. CET. Investors can access a live webcast of the session on investors.kenvue.com, with a replay available after the event.
Kenvue (NYSE: KVUE) has announced its global Kenvue Cares Week initiative, showcasing significant community engagement across 21 markets on six continents. The company's employees, known as Kenvuers, are contributing over 5,000 volunteer hours and assembling approximately 22,000 hygiene kits containing more than 110,000 products from brands like Neutrogena®, Listerine®, and Johnson's® Baby.
The program, which has seen a fourfold increase in site participation since its inaugural year, involves partnerships with organizations like Save the Children, Heart to Heart International, and various local nonprofits. Activities include disaster relief efforts, environmental initiatives, and community support programs across North America, Latin America, Europe, Middle East, Africa, and Asia-Pacific regions.
Kenvue (NYSE: KVUE) has appointed Amit Banati as its new Chief Financial Officer, effective May 12, 2025. Banati, a 30-year veteran in consumer products finance and operations, will succeed Paul Ruh and oversee Finance and Strategy functions. Banati joins from Kellanova (previously Kellogg Company) where he served as Vice Chairman and CFO, with prior experience at Kraft Foods, Cadbury Schweppes, and Procter & Gamble.
The new CFO brings significant international operations experience, particularly in Asia Pacific, Middle East, India, and Africa. His focus will be on supporting revenue growth through data management, resource allocation, margin improvement, strengthening cash flow, and fostering greater agility in business planning and financial forecasting.
Kenvue (NYSE: KVUE), the world's largest pure-play consumer health company by revenue, has scheduled its first quarter 2025 financial results announcement for May 8, 2025, before market open. The company will host a conference call and webcast at 8:00 a.m. Eastern Time to discuss the results.
Investors can access the conference call by dialing 877-407-8835 (U.S.) or +1 201-689-8779 (international). A live webcast will be available at investors.kenvue.com, with a replay accessible after the event.
Kenvue's portfolio includes renowned brands such as Aveeno, BAND-AID, Johnson's, Listerine, Neutrogena, and Tylenol, which are science-backed and recommended by healthcare professionals globally.
Kenvue (NYSE: KVUE) has announced a quarterly dividend declaration approved by its Board of Directors. The company will pay a dividend of $0.205 per share on its common stock. The dividend will be distributed on May 28, 2025, to shareholders who are recorded on the company's books at the close of business on May 14, 2025.